Feng Li-An, Shi Jie, Guo Jing-Yue, Wang Shu-Fang
Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Weijin Road 94, Tianjin 300071, China.
Institute of Disaster and Emergency Medicine, Tianjin University, Weijin Road 92, Tianjin 300072, China.
J Mater Chem B. 2022 May 25;10(20):3781-3792. doi: 10.1039/d2tb00478j.
Cardiovascular diseases have become one of the leading causes of mortality worldwide. Stents and artificial grafts have been used to treat cardiovascular diseases. Thrombosis and restenosis seriously impact the clinical outcome of stents and artificial vascular grafts. For the purpose of antithrombosis and anti-restenosis, numerous strategies have been developed to construct highly hemocompatible surfaces, enhance endothelialization, and inhibit intimal hyperplasia. Rapid endothelialization and inhibited intimal hyperplasia play an important role in artery repair after stent implantation and coronary artery bypass graft surgery. This review focuses on the recently developed strategies for improving the hemocompatibility and endothelialization of cardiovascular devices. We also introduce drug, gene and RNA delivery technologies for inhibiting intimal hyperplasia. The challenges and future perspectives about promoting endothelialization are also briefly discussed with the hope to help inspire further innovations.
心血管疾病已成为全球主要死因之一。支架和人工血管已被用于治疗心血管疾病。血栓形成和再狭窄严重影响支架和人工血管移植物的临床效果。为了抗血栓形成和抗再狭窄,人们已开发出多种策略来构建高度血液相容性表面、促进内皮化并抑制内膜增生。快速内皮化和抑制内膜增生在支架植入和冠状动脉旁路移植术后的动脉修复中发挥着重要作用。本综述重点关注近期开发的改善心血管装置血液相容性和内皮化的策略。我们还介绍了用于抑制内膜增生的药物、基因和RNA递送技术。还简要讨论了促进内皮化面临的挑战和未来前景,希望有助于激发进一步的创新。
Acta Biomater. 2019-8-24
J Biomed Mater Res A. 2013-8-24
J Invasive Cardiol. 2005-9
Surg Technol Int. 2020-5-28
Bioact Mater. 2024-6-29
BMC Cardiovasc Disord. 2024-5-31
Front Bioeng Biotechnol. 2024-1-24
Materials (Basel). 2023-11-19